Orally efficacious NR2B-selective NMDA receptor antagonists

Bioorg Med Chem Lett. 2003 Feb 24;13(4):697-700. doi: 10.1016/s0960-894x(02)01061-2.

Abstract

A novel series of benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 31 is orally active in a carrageenan-induced rat hyperalgesia model of pain and shows no motor coordination side effects.

MeSH terms

  • Administration, Oral
  • Animals
  • Benzamidines / chemical synthesis
  • Benzamidines / pharmacology*
  • Carrageenan
  • Drug Evaluation, Preclinical
  • Hyperalgesia / drug therapy
  • Pain / drug therapy
  • Psychomotor Performance / drug effects
  • Rats
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
  • Structure-Activity Relationship

Substances

  • Benzamidines
  • NR2B NMDA receptor
  • Receptors, N-Methyl-D-Aspartate
  • Carrageenan